Novo Nordisk plans to invest more than €2.1 billion to expand manufacturing capacity at its site in Chartres, France to support its current and future product portfolio. The expansion will more than double the footprint of the site and entails adding aseptic and finished production processes and extending its Quality Control lab.   The expansion program will increase manufacturing capacity for its GLP-1 products, namely Ozempic and Wegovy, to meet increasing and future demand.   The company ...